West Tower Group’s NovoCure NVCR Stock Holding History

West Tower Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-203	Closed	-$3.28K	–	681
2023 Q3	$3.28K	Buy	+203	New	+$5.85K	﹤0.01%	534

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

West Tower Group's NVCR Position: Q4 2023 in Review

West Tower Group sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 203 shares — an estimated $3.28K sold.

West Tower Group first reported a position in NVCR in Q3 2023 and held it in 1 quarter. The position peaked at $3.28K in Q3 2023. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

West Tower Group reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
West Tower Group sold 203 NovoCure shares in Q4 2023, an estimated $3.28K.
West Tower Group first reported a position in NovoCure in Q3 2023 and held it in 1 quarter.
West Tower Group's NovoCure position peaked at $3.28K in Q3 2023.
219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on West Tower Group's 13F filing for Q4 2023, filed 14 Feb 2024.